» Articles » PMID: 30655705

Summarizing and Communicating on Survival Data According to the Audience: a Tutorial on Different Measures Illustrated with Population-based Cancer Registry Data

Overview
Journal Clin Epidemiol
Publisher Dove Medical Press
Specialty Public Health
Date 2019 Jan 19
PMID 30655705
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Survival data analysis results are usually communicated through the overall survival probability. Alternative measures provide additional insights and may help in communicating the results to a wider audience. We describe these alternative measures in two data settings, the overall survival setting and the relative survival setting, the latter corresponding to the particular competing risk setting in which the cause of death is unavailable or unreliable. In the overall survival setting, we describe the overall survival probability, the conditional survival probability and the restricted mean survival time (restricted to a prespecified time window). In the relative survival setting, we describe the net survival probability, the conditional net survival probability, the restricted mean net survival time, the crude probability of death due to each cause and the number of life years lost due to each cause over a prespecified time window. These measures describe survival data either on a probability scale or on a timescale. The clinical or population health purpose of each measure is detailed, and their advantages and drawbacks are discussed. We then illustrate their use analyzing England population-based registry data of men 15-80 years old diagnosed with colon cancer in 2001-2003, aiming to describe the deprivation disparities in survival. We believe that both the provision of a detailed example of the interpretation of each measure and the software implementation will help in generalizing their use.

Citing Articles

Constructing individualized follow-up strategies for locally advanced esophageal squamous cell carcinoma patients based on dynamic recurrence risk changes.

Cai Y, Ding J, Cai X, Su W, Weng G, Zheng X Sci Rep. 2025; 15(1):175.

PMID: 39747490 PMC: 11695730. DOI: 10.1038/s41598-024-84099-4.


Beta-blocker initiation under dobutamine infusion in acute advanced heart failure: a target trial emulation with observational data.

Mori Y, Inoue K, Sato H, Tsushima T, Fukuma S Eur Heart J Open. 2024; 4(4):oeae054.

PMID: 39011092 PMC: 11247169. DOI: 10.1093/ehjopen/oeae054.


Trends in Net Survival from Vulvar Squamous Cell Carcinoma in Italy (1990-2015).

Mancini S, Bucchi L, Zamagni F, Baldacchini F, Crocetti E, Giuliani O J Clin Med. 2023; 12(6).

PMID: 36983173 PMC: 10054662. DOI: 10.3390/jcm12062172.


Individual frailty excess hazard models in cancer epidemiology.

Rubio F, Putter H, Belot A Stat Med. 2023; 42(7):1066-1081.

PMID: 36694108 PMC: 10560131. DOI: 10.1002/sim.9657.


Trends in Liver Cancer Incidence and Survival in Italy by Histologic Type, 2003-2017.

Mancini S, Bucchi L, Zamagni F, Guzzinati S, Dal Maso L, Rugge M Cancers (Basel). 2022; 14(24).

PMID: 36551647 PMC: 9777051. DOI: 10.3390/cancers14246162.


References
1.
Cronin K, Feuer E . Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med. 2000; 19(13):1729-40. DOI: 10.1002/1097-0258(20000715)19:13<1729::aid-sim484>3.0.co;2-9. View

2.
Diez Roux A . Investigating neighborhood and area effects on health. Am J Public Health. 2001; 91(11):1783-9. PMC: 1446876. DOI: 10.2105/ajph.91.11.1783. View

3.
Chen P, Tsiatis A . Causal inference on the difference of the restricted mean lifetime between two groups. Biometrics. 2002; 57(4):1030-8. DOI: 10.1111/j.0006-341x.2001.01030.x. View

4.
Hardie K, Hankey G, Jamrozik K, Broadhurst R, Anderson C . Ten-year survival after first-ever stroke in the perth community stroke study. Stroke. 2003; 34(8):1842-6. DOI: 10.1161/01.STR.0000082382.42061.EE. View

5.
Skuladottir H, Olsen J . Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. J Clin Oncol. 2003; 21(16):3035-40. DOI: 10.1200/JCO.2003.04.521. View